Janus Henderson Group
RVNC

Janus Henderson Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Janus Henderson Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-38,107
Closed -$116K – 2579
2024
Q4 		$116K Hold
38,107
– – ﹤0.01% 2502
2024
Q3 		$198K Hold
38,107
– – ﹤0.01% 2433
2024
Q2 		$98.1K Sell
38,107
-435
-1% -$1.49K ﹤0.01% 2502
2024
Q1 		$189K Buy
38,542
+3
+0% +$18 ﹤0.01% 2436
2023
Q4 		$339K Sell
38,539
-60
-0.2% -$492 ﹤0.01% 2178
2023
Q3 		$443K Buy
38,599
+24
+0.1% +$461 ﹤0.01% 1986
2023
Q2 		$976K Sell
38,575
-51
-0.1% -$1.59K ﹤0.01% 1627
2023
Q1 		$1.24M Buy
38,626
+24,831
+180% +$774K ﹤0.01% 1509
2022
Q4 		$255K Sell
13,795
-33,795
-71% -$773K ﹤0.01% 2053
2022
Q3 		$1.28M Buy
47,590
+33,824
+246% +$686K ﹤0.01% 1519
2022
Q2 		$190K Sell
13,766
-19
-0.1% -$293 ﹤0.01% 2325
2022
Q1 		$269K Buy
13,785
+1
+0% +$15 ﹤0.01% 2287
2021
Q4 		$225K Buy
+13,784
New +$230K ﹤0.01% 2336

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Janus Henderson Group's RVNC Position: Q1 2025 in Review

Janus Henderson Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 38,107 shares — an estimated $116K sold.

Janus Henderson Group first reported a position in RVNC in Q4 2021 and held it in 13 quarters. The position peaked at $1.28M in Q3 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Janus Henderson Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Janus Henderson Group sold 38,107 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $116K.
  • Janus Henderson Group first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 13 quarters.
  • Janus Henderson Group's Revance Therapeutics, Inc. position peaked at $1.28M in Q3 2022.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Janus Henderson Group's 13F filing for Q1 2025, filed 15 May 2025.